Article
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jan 2025
André F, Solovieff N, Su F, Bardia A, Neven P, Yap Y S, Tripathy D, Lu Y-S, Slamon D, Chia S, Joshi M, Chakravartty A, Lteif A, Taran T, Arteaga C L
Abstract excerpt
BACKGROUND: A prior pooled analysis of the MONALEESA-2, -3, and -7 trials identified baseline markers predictive of sensitivity or resistance to ribociclib plus endocrine therapy (ET). We report the results of an analysis of paired baseline and end-of-treatment (EOT) circulating tumor DNA (ctDNA) samples across the MONALEESA trials. PATIENTS AND METHODS: Paired baseline and EOT ctDNA samples from MONALEESA-2, -3,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.